Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940032 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11CMA1PTGS2CA2 | |
| SCHEMBL1016405 | 0.83 | CCR2 (0.37) | NR1H2CCR2RIPK1 | |
| SCHEMBL31734456 | 0.83 | CCR2 (0.37) | NR1H2CCR2RIPK1 | |
| SCHEMBL22968036 | 0.81 | GSTO1 (0.48) | CYP4F2CYP4A11RIPK1 | |
| SCHEMBL48582 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11NR1H2CCR2RIPK1 | |
| SCHEMBL21038420 | 0.80 | ESR1 (0.38) | NR1H2CCR2RIPK1 | |
| SCHEMBL1495564 | 0.79 | CMA1 (0.41) | CYP4F2CYP4A11CMA1PTGS2CA2 | |
| SCHEMBL27807461 | 0.79 | CCR2 (0.35) | NR1H2CCR2 | |
| SCHEMBL28326069 | 0.79 | CCR2 (0.35) | NR1H2CCR2RIPK1 | |
| SCHEMBL2910230 | 0.78 | CA2 (0.41) | CMA1PTGS2CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| CN-106536525-B | Compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-7985863-B2 | Iminopyridine derivatives and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7982044-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP4F2 3043/4885CYP4A11 1952/4885CMA1 488/4885 |
| US-20190023715-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP4F2 3043/4885CYP4A11 1952/4885CMA1 488/4885 |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | CYP4F2 2544/4885CYP4A11 985/4885CMA1 900/4885 |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | CYP4F2 2544/4885CYP4A11 985/4885CMA1 900/4885 |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | ADRA1D, ADRB1, ADRB2 | CYP4F2 2603/4885CYP4A11 1131/4885CMA1 906/4885 |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | CYP4F2 2544/4885CYP4A11 985/4885CMA1 900/4885 |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | CYP4F2 2544/4885CYP4A11 985/4885CMA1 900/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP4F2 3043/4885CYP4A11 1952/4885CMA1 488/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP4F2 3043/4885CYP4A11 1952/4885CMA1 488/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP4F2 3043/4885CYP4A11 1952/4885CMA1 488/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | CYP4F2 2544/4885CYP4A11 985/4885CMA1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.